pharmaceuticals Archives - Page 3 of 5

Rompharm Company decreased its stake in Sopharma from c.18% to 9.41%

11 December 2017

Rompharm Company decreased its stake in Sopharma from c.18% to 9.41%, according to a regulatory filing. Sopharma informed that Rompharm Company has sold almost half of its stake in the Company and currently has 9.41% as of Dec 8th, 2017.

Sopharma Trading receives green light to acquire PharmaStore

9 November 2017

The Commission for Protection of Competition in Bulgaria has approved Sopharma Trading (SO5 BU)’s acquisition of the local PharmaStore harmacies chain. The Regulator’s decision comes after the company announced in March this year that it has reached the agreement for the acquisition of PharmaStore pharmacies operations (19 pharmacies in Bulgaria), with the intention of subsequently… Read more

Sopharma with long-term contract to supply cytisine to USA

27 October 2017

The US pharmaceutical company Achieve Life Sciences (NASDAQ: ACHV) has entered into an exclusive supply agreement with leading pharmaceutical producer Sopharma (3JR BU) to manufacture cytisine active pharmaceutical ingredient (API) and finished tablets, according to a statement by Achieve. How smoking cessation cytisine based drug Tabex made entrance in US In 2015, Achieve acquired from… Read more

A step further for Sopharma’s Tabex in the US

15 August 2017

Smoking cessation drug Tabex US rights holder Achieve Life Sciences closes merger with OngoGenex Pharmaceuticals, according to a regulatory filing by the latter. Cytisine has been an established treatment produced and marketed in Central and Eastern Europe by Sopharma for 15+ years under the brand of Tabex. The road of Tabex to US Leading generic… Read more

Sopharma Trading books 9.3% y/y rise in sales in H1 2017

2 August 2017

Sopharma Trading (SO BU) books 9.3% y/y rise in sales in H1’17 to BGN 325m, gross profit up 10.2% y/y to BGN 24.4m, according to the Company’s interim standalone financial report as of June 30th, 2017. Net profit is up 11.2% y/y to BGN 7.2m. Green light for Sopharma Trading acquisition in Serbia In July… Read more

Sopharma books 50% y/y rise in EBITDA in H1 2017

1 August 2017

Leading generic drugs producer Sopharma (3JR BU) booked 50.3% y/y rise in EBITDA to BGN 32m in H1 2017 on 18% y/y surge in sales, according to the Company’s interim standalone financial statement as of June 30th 2017. Sopharma sales in Russia and Ukraine recover Sopharma H1 sales advanced in line with preliminary estimates with… Read more

New equity research report: Sopharma’s recovery is speeding up

20 July 2017

Sopharma, the leading generic pharmaceutical company in Bulgaria, is recovering faster than expected from the Russia/Ukraine conflict on strong exports – this was concluded in the latest equity research report by ELANA Trading analysts covering Q1 2017 earnings of Sopharma. Sopharma’s top line recovery speeding up Sopharma’s top line is recovering faster than ELANA Trading’s… Read more

Sopharma Trading to acquire Serbian pharma distributor

28 June 2017

Biggest pharma distributor in Bulgaria Sopharma Trading (SO5 BU) to acquire Serbian pharma distributor Lekovit, according to a filing by the former. The acquisition is subject to an antitrust approval. Pharma stores acquisitions on the agenda The deal is part of Sopharma Trading’s plans to expand in Serbia and gain market share. The Company began… Read more

SEC approves merger on Sopharma’s Tabex US right holder

16 June 2017

US Securities and Exchange Commission approved of Sopharma’s (3JR BU) Tabex US rights holder merger, according to an announcement by Sopharma. The SEC approved the merger between Achieve Live Science and OncoGenex Pharmaceuticals with the latter expected to be approved by OncoGenex’ shareholders on Aug 1st 2017. Tabex walk to US In 2015 Sopharma sold… Read more

Sopharma proposes 42% higher dividend per share this year, 2.5% yield

5 May 2017

Generic pharma producer Sopharma (3JR BU) is proposing 42% y/y higher dividend per share of BGN 0.10 from 2016 profits, according to forthcoming annual shareholders meeting. This is the first dividend raise since 2010. The decision is to be approved at the annual shareholders meeting scheduled for June 2nd, 2017. The proposed dividend yields 2.5%… Read more